Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Renal Cell Carcinoma
59%
Advanced Renal Cell Carcinoma (aRCC)
57%
Metastatic Renal Cell Carcinoma (mRCC)
54%
Nivolumab
47%
Ipilimumab
34%
Sunitinib
30%
Immune Checkpoint Inhibitors
26%
Kidney Cancer
19%
Overall Survival
18%
Progression-free Survival
15%
Tumor
14%
Systemic Therapy
12%
Phase I Study
11%
Pembrolizumab
11%
Everolimus
11%
Stereotactic Ablative Radiotherapy
10%
Clear Cell Renal Cell Carcinoma (ccRCC)
10%
CheckMate 214
10%
Objective Response Rate
10%
Treatment Lines
9%
Cabozantinib
9%
Hazard Ratio
9%
Histone Deacetylase Inhibitor (HDACi)
8%
Treatment-related Adverse Events
8%
Immune-related Adverse Events (IrAEs)
8%
Clinical Trials
7%
Randomized Phase III Trial
7%
Vascular Endothelial Growth Factor
7%
Antitumor Activity
7%
Monotherapy
7%
Tumor Microenvironment
6%
95% Confidence Interval
6%
Prostate Cancer
6%
Non-clear Cell Renal Cell Carcinoma
6%
Cancer Research
6%
Hypoxia-inducible factor-1α (HIF-1α)
6%
Favorable Risk
6%
Programmed Cell Death Protein 1 (PD-1)
6%
Cancer Immunotherapy
6%
Tumor Growth
6%
CheckMate 025
6%
Cytoreductive Nephrectomy
6%
Research Summit
6%
Phase II Trial
6%
Survival Outcomes
6%
Poor Risk
5%
Response Rate
5%
Advanced or Metastatic
5%
Targeted Therapy
5%
Adverse Events
5%
Medicine and Dentistry
Clear Cell Renal Cell Carcinoma
100%
Nivolumab
40%
Kidney Metastasis
35%
Immunotherapy
27%
Ipilimumab
21%
Sunitinib
20%
Overall Survival
19%
Immune Checkpoint Inhibitor
19%
Kidney Cancer
17%
Neoplasm
17%
Systemic Therapy
15%
Progression Free Survival
15%
Malignant Neoplasm
12%
Radiation Therapy
12%
Nephrectomy
12%
Sodium Fluoride
11%
Adverse Event
11%
Diseases
10%
Clinical Trial
9%
Pembrolizumab
9%
Everolimus
8%
Cabozantinib
8%
Tumor Progression
8%
Arm
7%
Metastatic Carcinoma
7%
Tumor
7%
Hazard Ratio
6%
Vasculotropin
6%
Biological Marker
6%
Tyrosine-Kinase Inhibitor
5%
Histology
5%
Pharmacology, Toxicology and Pharmaceutical Science
Renal Cell Carcinoma
54%
Nivolumab
41%
Ipilimumab
21%
Sunitinib
20%
Kidney Metastasis
18%
Overall Survival
16%
Adverse Event
14%
Malignant Neoplasm
14%
Sodium Fluoride
13%
Immune Checkpoint Inhibitor
13%
Neoplasm
11%
Immunotherapy
11%
Everolimus
10%
Progression Free Survival
9%
Kidney Cancer
8%
Prostate Cancer
8%
Cabozantinib
7%
Histone Deacetylase Inhibitor
7%
Tumor Growth
7%
Monotherapy
5%
Clinical Trial
5%
Pembrolizumab
5%
Melanoma
5%
Biological Marker
5%